Dendritic cells transfected with interleukin-12 and pulsed withtumor extract inhibit growth of murine prostatic carcinoma in vivo

Shaobo Zhang, Guangyuan Zeng, David S. Wilkes, Gerry E. Reed, Ronald C. McGarry, John N. Eble, Liang Cheng

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

BACKGROUND. The induction of anti-tumor immune response by injection of dendritic cells loaded with specific antigen or transduced with genes encoding tumor-specific antigens have been studied in animal models and have shown promising anti-tumor effects. The impact of different routes of administration of dendritic cells on their anti-tumor effects is uncertain. METHODS. We examined the effect of injection of cloned dendritic cells, which were stably transfected with IL-12 and exposed to an extract of murine RM-9 prostate carcinoma cell antigens on tumor growth in vivo. The cloned dendritic cells were injected intramuscularly, subcutaneously, or intraperitoneally into C57BL/6 mice. Seven days later, the mice were inoculated subcutaneously with 100,000 RM-9 cells. The sizes of the resulting tumors were measured every 3 days. RESULTS. Compared with the wild type dendritic cells, the IL-12-transfected dendritic cells delayed tumor engraftment by 7 days (P = 0.04), and reduced tumor growth by up to 80% (P = 0.02). Among the three routes of injection, intramuscular injection was most effective. In contrast to wild type dendritic cells, IL-12-transfected dendritic cells induced infiltration of mononuclear cells into the tumors, and induced apoptosis and necrosis of tumor cells. Injection of IL-12-transfected dendritic cells also significantly delays tumor growth in the preexisting RM-9 tumors. CONCLUSIONS. We conclude that antigen-exposed, IL-12-transfected dendritic cells have potential as an immunotherapy for prostate carcinoma. Routes of administration of dendritic cells are critical for maximal anti-tumor effect.

Original languageEnglish (US)
Pages (from-to)292-298
Number of pages7
JournalProstate
Volume55
Issue number4
DOIs
StatePublished - Jun 1 2003

Fingerprint

Interleukin-12
Dendritic Cells
Carcinoma
Growth
Neoplasms
Injections
Neoplasm Antigens
Prostate
Antigens
Intramuscular Injections
Inbred C57BL Mouse
Immunotherapy
Necrosis
Animal Models
Apoptosis

Keywords

  • Dendritic cells
  • Gene therapy
  • Interleukin-12
  • Prostate
  • Transfection

ASJC Scopus subject areas

  • Urology

Cite this

Dendritic cells transfected with interleukin-12 and pulsed withtumor extract inhibit growth of murine prostatic carcinoma in vivo. / Zhang, Shaobo; Zeng, Guangyuan; Wilkes, David S.; Reed, Gerry E.; McGarry, Ronald C.; Eble, John N.; Cheng, Liang.

In: Prostate, Vol. 55, No. 4, 01.06.2003, p. 292-298.

Research output: Contribution to journalArticle

Zhang, Shaobo ; Zeng, Guangyuan ; Wilkes, David S. ; Reed, Gerry E. ; McGarry, Ronald C. ; Eble, John N. ; Cheng, Liang. / Dendritic cells transfected with interleukin-12 and pulsed withtumor extract inhibit growth of murine prostatic carcinoma in vivo. In: Prostate. 2003 ; Vol. 55, No. 4. pp. 292-298.
@article{6700a9bd8c074855b6c1e76fa230972a,
title = "Dendritic cells transfected with interleukin-12 and pulsed withtumor extract inhibit growth of murine prostatic carcinoma in vivo",
abstract = "BACKGROUND. The induction of anti-tumor immune response by injection of dendritic cells loaded with specific antigen or transduced with genes encoding tumor-specific antigens have been studied in animal models and have shown promising anti-tumor effects. The impact of different routes of administration of dendritic cells on their anti-tumor effects is uncertain. METHODS. We examined the effect of injection of cloned dendritic cells, which were stably transfected with IL-12 and exposed to an extract of murine RM-9 prostate carcinoma cell antigens on tumor growth in vivo. The cloned dendritic cells were injected intramuscularly, subcutaneously, or intraperitoneally into C57BL/6 mice. Seven days later, the mice were inoculated subcutaneously with 100,000 RM-9 cells. The sizes of the resulting tumors were measured every 3 days. RESULTS. Compared with the wild type dendritic cells, the IL-12-transfected dendritic cells delayed tumor engraftment by 7 days (P = 0.04), and reduced tumor growth by up to 80{\%} (P = 0.02). Among the three routes of injection, intramuscular injection was most effective. In contrast to wild type dendritic cells, IL-12-transfected dendritic cells induced infiltration of mononuclear cells into the tumors, and induced apoptosis and necrosis of tumor cells. Injection of IL-12-transfected dendritic cells also significantly delays tumor growth in the preexisting RM-9 tumors. CONCLUSIONS. We conclude that antigen-exposed, IL-12-transfected dendritic cells have potential as an immunotherapy for prostate carcinoma. Routes of administration of dendritic cells are critical for maximal anti-tumor effect.",
keywords = "Dendritic cells, Gene therapy, Interleukin-12, Prostate, Transfection",
author = "Shaobo Zhang and Guangyuan Zeng and Wilkes, {David S.} and Reed, {Gerry E.} and McGarry, {Ronald C.} and Eble, {John N.} and Liang Cheng",
year = "2003",
month = "6",
day = "1",
doi = "10.1002/pros.10246",
language = "English (US)",
volume = "55",
pages = "292--298",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Dendritic cells transfected with interleukin-12 and pulsed withtumor extract inhibit growth of murine prostatic carcinoma in vivo

AU - Zhang, Shaobo

AU - Zeng, Guangyuan

AU - Wilkes, David S.

AU - Reed, Gerry E.

AU - McGarry, Ronald C.

AU - Eble, John N.

AU - Cheng, Liang

PY - 2003/6/1

Y1 - 2003/6/1

N2 - BACKGROUND. The induction of anti-tumor immune response by injection of dendritic cells loaded with specific antigen or transduced with genes encoding tumor-specific antigens have been studied in animal models and have shown promising anti-tumor effects. The impact of different routes of administration of dendritic cells on their anti-tumor effects is uncertain. METHODS. We examined the effect of injection of cloned dendritic cells, which were stably transfected with IL-12 and exposed to an extract of murine RM-9 prostate carcinoma cell antigens on tumor growth in vivo. The cloned dendritic cells were injected intramuscularly, subcutaneously, or intraperitoneally into C57BL/6 mice. Seven days later, the mice were inoculated subcutaneously with 100,000 RM-9 cells. The sizes of the resulting tumors were measured every 3 days. RESULTS. Compared with the wild type dendritic cells, the IL-12-transfected dendritic cells delayed tumor engraftment by 7 days (P = 0.04), and reduced tumor growth by up to 80% (P = 0.02). Among the three routes of injection, intramuscular injection was most effective. In contrast to wild type dendritic cells, IL-12-transfected dendritic cells induced infiltration of mononuclear cells into the tumors, and induced apoptosis and necrosis of tumor cells. Injection of IL-12-transfected dendritic cells also significantly delays tumor growth in the preexisting RM-9 tumors. CONCLUSIONS. We conclude that antigen-exposed, IL-12-transfected dendritic cells have potential as an immunotherapy for prostate carcinoma. Routes of administration of dendritic cells are critical for maximal anti-tumor effect.

AB - BACKGROUND. The induction of anti-tumor immune response by injection of dendritic cells loaded with specific antigen or transduced with genes encoding tumor-specific antigens have been studied in animal models and have shown promising anti-tumor effects. The impact of different routes of administration of dendritic cells on their anti-tumor effects is uncertain. METHODS. We examined the effect of injection of cloned dendritic cells, which were stably transfected with IL-12 and exposed to an extract of murine RM-9 prostate carcinoma cell antigens on tumor growth in vivo. The cloned dendritic cells were injected intramuscularly, subcutaneously, or intraperitoneally into C57BL/6 mice. Seven days later, the mice were inoculated subcutaneously with 100,000 RM-9 cells. The sizes of the resulting tumors were measured every 3 days. RESULTS. Compared with the wild type dendritic cells, the IL-12-transfected dendritic cells delayed tumor engraftment by 7 days (P = 0.04), and reduced tumor growth by up to 80% (P = 0.02). Among the three routes of injection, intramuscular injection was most effective. In contrast to wild type dendritic cells, IL-12-transfected dendritic cells induced infiltration of mononuclear cells into the tumors, and induced apoptosis and necrosis of tumor cells. Injection of IL-12-transfected dendritic cells also significantly delays tumor growth in the preexisting RM-9 tumors. CONCLUSIONS. We conclude that antigen-exposed, IL-12-transfected dendritic cells have potential as an immunotherapy for prostate carcinoma. Routes of administration of dendritic cells are critical for maximal anti-tumor effect.

KW - Dendritic cells

KW - Gene therapy

KW - Interleukin-12

KW - Prostate

KW - Transfection

UR - http://www.scopus.com/inward/record.url?scp=0038136974&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038136974&partnerID=8YFLogxK

U2 - 10.1002/pros.10246

DO - 10.1002/pros.10246

M3 - Article

C2 - 12712408

AN - SCOPUS:0038136974

VL - 55

SP - 292

EP - 298

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 4

ER -